2023
Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study
Grinblatt D, Roboz G, Pollyea D, Sekeres M, Scott B, Seiter K, Zeidan A, Patel J, Garcia-Manero G, Komrokji R, Savona M, Degutis I, Kiselev P, Yu E, Heydendael W, Qiu Y, Vergara S, McBride A, Erba H. Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study. Blood 2023, 142: 593. DOI: 10.1182/blood-2023-189963.Peer-Reviewed Original ResearchAcute myeloid leukemiaYears of ageMedian overall survivalProportion of patientsOverall survivalRate of transplantGroup 2Group 1Molecular testingTreatment patternsAML cohortMedian (95% CI) OSMyeloid diseasesReal-world clinical practiceWorld Health Organization criteriaIntensive chemotherapy regimensLow-intensity chemotherapyObservational cohort studyOutcomes of patientsFirst-line treatmentKaplan-Meier methodProspective observational studyYear of diagnosisDate of diagnosisTreatment of patients
2019
A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Sekeres M, Schuster M, Joris M, Krauter J, Maertens J, Gyan E, Kovacsovics T, Verma A, Vyas P, Wang E, Wendy W, Zeremski M, Kudla A, Chan G, Zeidan A. A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia. Blood 2019, 134: 177. DOI: 10.1182/blood-2019-124050.Peer-Reviewed Original ResearchHigh-risk myelodysplastic syndromeChronic myelomonocytic leukemiaAcute myeloid leukemiaLow-dose cytarabineMedian treatment durationComplete remissionPhase 1b trialIntensive chemotherapyOverall survivalMyelodysplastic syndromePersonal feesAdverse eventsMyelomonocytic leukemiaSpeakers bureauSerious TEAEsFebrile neutropeniaMedian ageMedian timeEuropean LeukemiaNetRisk categoriesMyeloid leukemiaMedian (95% CI) OSMortality rateTreatment durationCR/complete remission